Jørgen Bente, Merckoll Patricia, Melby Kjetil K
Ullevål University Hospital, Oslo, Norway.
Scand J Infect Dis. 2007;39(11-12):1059-62. doi: 10.1080/00365540701466231. Epub 2007 Jul 30.
Our study compared the susceptibility of 136 clinical isolates of Staphylococcus aureus and 119 multidrug-resistant Staphylococcus aureus (MRSA) isolates from Oslo to a range of antibiotics, including the novel antibiotics quinupristin-dalfopristin, linezolid and daptomycin. All isolates were susceptible to daptomycin, linezolid and quinupristin-dalfopristin, although a subgroup was less susceptible to the latter. There was no linkage between reduced susceptibility to daptomycin, linezolid or quinupristin-dalfopristin and resistance to other classes of antimicrobials. In addition, MRSA strains from 2004 have become more sensitive to fucidin and rifampicin. The results can be used to evaluate the appropriateness of breakpoints and to define a baseline for monitoring possible future emergence of resistance to daptomycin, quinupristin-dalfopristin and linezolid in Staphylococcus aureus in Norway.
我们的研究比较了来自奥斯陆的136株金黄色葡萄球菌临床分离株和119株耐多药金黄色葡萄球菌（MRSA）分离株对一系列抗生素的敏感性，这些抗生素包括新型抗生素奎奴普丁-达福普汀、利奈唑胺和达托霉素。所有分离株对达托霉素、利奈唑胺和奎奴普丁-达福普汀均敏感，尽管有一个亚组对后者的敏感性较低。对达托霉素、利奈唑胺或奎奴普丁-达福普汀敏感性降低与对其他类抗菌药物耐药之间没有关联。此外，2004年的MRSA菌株对夫西地酸和利福平变得更敏感。这些结果可用于评估断点的适宜性，并为监测挪威金黄色葡萄球菌未来可能出现的对达托霉素、奎奴普丁-达福普汀和利奈唑胺耐药性确定一个基线。
